1. Introduction {#sec1-ijms-19-02329}
===============

With the acceleration of the size of the aging population, the world is now experiencing the "aging era" characterized by an increased incidence of neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD) \[[@B1-ijms-19-02329]\]. Neurodegenerative diseases represent a heterogeneous group of disorders whose common characteristic is the progressive and selective loss of neurons. Although many studies have been carried out to understand the pathophysiology of neurodegenerative diseases over the years, more efforts are still needed to uncover the processes that trigger these disorders. Despite different aetiologies, neurodegenerative disorders share common features like abnormal protein aggregation, perturbed Ca^2+^ homeostasis, excitotoxicity, impairment of mitochondrial functions, apoptosis, inflammation, and oxidative stress \[[@B2-ijms-19-02329],[@B3-ijms-19-02329]\]. Oxidative stress is an imbalance between accumulation and removal of reactive oxygen species (ROS). The brain is especially susceptible to oxidative stress due to its high oxygen consumption, high content of oxidizable polyunsaturated fatty acids, and low level of endogenous antioxidants and antioxidant enzymes \[[@B4-ijms-19-02329],[@B5-ijms-19-02329],[@B6-ijms-19-02329]\]. It has been shown that oxidative stress is involved in the onset and progression of neurodegenerative diseases like PD \[[@B2-ijms-19-02329],[@B7-ijms-19-02329],[@B8-ijms-19-02329],[@B9-ijms-19-02329],[@B10-ijms-19-02329]\] and AD \[[@B11-ijms-19-02329],[@B12-ijms-19-02329],[@B13-ijms-19-02329]\].

Despite recent advances in the research of biomarkers, early diagnosis, and pharmacotherapy, there are no treatments that can halt the progression or reverse the brain changes of any age-associated neurodegenerative diseases. This is likely due to the multifactorial nature of these pathologies that arise from a confluence of multiple, toxic insults.

Diet is considered one of the most important factors in lifestyle. Diet strongly influences the occurrence of cardiovascular and neurodegenerative diseases and, hence, a healthy lifestyle can be related to healthy aging \[[@B14-ijms-19-02329]\]. Numerous epidemiological studies indicate that long-term intake of a Mediterranean diet, characterized by a high consumption of extra virgin olive oil, correlates with better cognition in aged populations \[[@B15-ijms-19-02329],[@B16-ijms-19-02329],[@B17-ijms-19-02329]\]. Olive oil phenolic compounds have been demonstrated to possess different biological activities like antioxidant \[[@B18-ijms-19-02329]\], antithrombotic \[[@B19-ijms-19-02329]\], and anti-inflammatory \[[@B20-ijms-19-02329]\] activities. Oleocanthal, a dialdehydic form of (−)-deacetoxyligstroside glycoside, is one of the phenolic components of extra virgin olive oil \[[@B21-ijms-19-02329]\]. Even though oleocanthal makes up only 10% of the olive's phenols, it is getting more and more scientific attention due to its interesting biological activities \[[@B22-ijms-19-02329],[@B23-ijms-19-02329]\]. Oleocanthal is responsible for the bitter and pungent taste of extra virgin olive oil, and has anti-inflammatory properties similar to the nonsteroidal anti-inflammatory drug ibuprofen \[[@B24-ijms-19-02329]\]. In vitro, it has been shown that oleocanthal is effective on the key mediators of AD pathogenesis, amyloid-β and hyper-phosphorylated tau proteins \[[@B25-ijms-19-02329],[@B26-ijms-19-02329],[@B27-ijms-19-02329],[@B28-ijms-19-02329]\], which contribute significantly to neurodegeneration and memory loss \[[@B29-ijms-19-02329]\]. Moreover, oleocanthal reduces astrocyte activation and interleukin-1β levels in vivo \[[@B21-ijms-19-02329]\]. Studies on the antioxidant activities of oleocanthal are limited. Only one study carried out in isolated human monocytes showed that oleocanthal inhibits nicotinamide adenine dinucleotide phosphate oxidase (NOX) activity and reduces the intracellular level of superoxide anion \[[@B30-ijms-19-02329]\].

The aim of this research was to characterize the neuroprotective effects of oleocanthal against H~2~O~2~-induced oxidative stress in the neuron-like SH-SY5Y cell line. Moreover, protein expression profiling, combined with pathways analyses, was used to investigate the molecular events related to the protective effects, and to gain insight into the underlying mechanisms of neuroprotection and oxidative damage.

2. Results {#sec2-ijms-19-02329}
==========

2.1. Neuroprotective Effects of Oleocanthal against H~2~O~2~-Induced Damage {#sec2dot1-ijms-19-02329}
---------------------------------------------------------------------------

To investigate the potential cytotoxicity of oleocanthal, differentiated SH-SY5Y cells were treated with different concentrations (1--10 µM) of oleocanthal for 24 h ([Figure 1](#ijms-19-02329-f001){ref-type="fig"}a). Of note, oleocanthal did not show any effect on cell viability at any tested concentrations. To study the potential protective activity of oleocanthal against oxidative injury, cells were treated with increasing concentrations (1--10 µM) of oleocanthal before the induction of oxidative stress by 700 µM H~2~O~2~ exposure for 1 h ([Figure 1](#ijms-19-02329-f001){ref-type="fig"}c). This peroxide concentration has been chosen as it reduces cell viability by 50% with respect to control cells ([Figure 1](#ijms-19-02329-f001){ref-type="fig"}b). Moreover, similar H~2~O~2~ concentrations have been recently used by Piras et al. \[[@B31-ijms-19-02329]\] in differentiated SH-SY5Y cells.

Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide (MTT) assay. As expected, H~2~O~2~ significantly reduced cell viability with respect to control cells. Quantities of 1 to 5 µM oleocanthal were not able to counteract peroxide's deleterious effects as cell viability was comparable to that of H~2~O~2~-treated cells. On the contrary, 10 µM oleocanthal significantly increased cell viability with respect to H~2~O~2~-treated cells. For these reasons, the subsequent experiments were carried out using 10 µM oleocanthal.

2.2. Antioxidant Activity of Oleocanthal against H~2~O~2~-Induced Oxidative Stress {#sec2dot2-ijms-19-02329}
----------------------------------------------------------------------------------

The ability of oleocanthal to counteract H~2~O~2~-induced intracellular ROS production was investigated by the 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) assay. As illustrated in [Figure 2](#ijms-19-02329-f002){ref-type="fig"}, incubation of differentiated SH-SY5Y cells with H~2~O~2~ resulted in a significant and marked increase in intracellular ROS levels. Oleocanthal, in contrast, significantly reduced intracellular ROS levels compared to H~2~O~2~. There was no change in ROS levels after treatment with oleocanthal alone.

As GSH is the most abundant endogenous antioxidant \[[@B32-ijms-19-02329]\], we next evaluated the effect of oleocanthal treatment in the absence/presence of H~2~O~2~ on intracellular GSH levels by monochlorobimane (MCB) assay ([Figure 3](#ijms-19-02329-f003){ref-type="fig"}). Interestingly, oleocanthal alone was able to increase GSH levels compared with control cells. Exposure to H~2~O~2~ caused a significant decrease in GSH levels; meanwhile, pretreatment with oleocanthal significantly increased the amount of GSH compared with in H~2~O~2~-treated cells.

2.3. Protein Expression Analysis {#sec2dot3-ijms-19-02329}
--------------------------------

[Figure 4](#ijms-19-02329-f004){ref-type="fig"} illustrates a representative two-dimensional electrophoresis (2DE) image of differentiated SH-SY5Y human neuroblastoma cellular protein extracts. The quality of the gels was assessed by the software Same Spot which includes the SpotCheck function. SpotCheck is a separate quality control workflow which allowed us to objectively assess the quality of our gels images. We selected a "gold standard" gel (a reference gel) and each gel was tested against it; the software confirmed that we ran gels in a reproducible manner.

Overall, an average of 1100 ± 150 spots was found within a nonlinear pH range from 3 to 10.

Normalized spot volumes were analyzed by the ANOVA test to detect the proteins which were significantly (*p* \< 0.05, *q* value \< 0.05) differentially expressed among different comparisons. Regarding comparison with the control of the 46 spots detected as modified by the treatment with H~2~O~2~, 6 were up- and 40 down-regulated. Twelve spots were found differentially expressed in cells treated with oleocanthal; 5 were up- and 7 down-regulated. Finally, of the 46 spots significantly modified by the addition of oleocanthal + H~2~O~2~, 14 were up- and 32 down-regulated.

To investigate the protection of oleocanthal against the detrimental effect of H~2~O~2~, a comparison between oleocanthal + H~2~O~2~ vs. H~2~O~2~ was carried out. A volcano plot was constructed to represent fold change in protein expression ([Figure 5](#ijms-19-02329-f005){ref-type="fig"}). By this way, 31 spots were found with significant change of expression; 22 were up- and 9 down-regulated.

All spots of interest were selected and excised from the gel and identified by nano-LC-ESI-MS/MS.

A list of identified proteins, with molecular weight (MW), isoelectric point (pI), score, and coverage values of MS/MS is shown in [Table 1](#ijms-19-02329-t001){ref-type="table"}, while [Table 2](#ijms-19-02329-t002){ref-type="table"} and [Table 3](#ijms-19-02329-t003){ref-type="table"} show the protein names, ratio, and *p* values of proteins resulting as significantly changed in the comparison between H~2~O~2~ vs. control and oleocanthal + H~2~O~2~ vs. H~2~O~2~, respectively.

2.4. Pathway and Network Analysis {#sec2dot4-ijms-19-02329}
---------------------------------

For the oleocanthal + H~2~O~2~ vs. H~2~O~2~ comparison, proteins found differentially expressed were included in the Ingenuity Pathways Analysis (IPA) analysis to identify molecular and cellular functions and to investigate whether these proteins work together in specific networks. Therefore, the software generated a main network ([Figure 6](#ijms-19-02329-f006){ref-type="fig"}) with associated biofunctions "Cancer, Organismal Injury, and Abnormalities" and focused on canonical pathways which showed our differentially expressed molecules to fall into functional categories such as protein synthesis, protein degradation, cell death and survival, and cellular function and maintenance. All the proteins found to be up- and down-regulated may concur in an upstream regulator analysis to predict if transcription factors or genes could be activated or inactivated in agreement with the *z*-score value (*z*-score \> 2 and *p* \< 0.05). Two activated transcription regulators were found: MYCN (*z* = 2.0) and NFE2L2 (*z* = 2.17). Furthermore, hypothetical activated and inhibited master regulators in derived causal networks were suggested by the analysis ([Table 4](#ijms-19-02329-t004){ref-type="table"}).

2.5. Transcriptional Validation of Proteomic Data Using RT-Polymerase Chain Reaction (PCR) Assays {#sec2dot5-ijms-19-02329}
-------------------------------------------------------------------------------------------------

We selected 9 genes encoding significantly expressed proteins for RT-PCR validation: HSP90AA1, HSP90AB1 which encode for the isoforms α and β of the heat shock protein Hsp90; PSMD1, PSMB4, and USP14 which encode for proteasome 26S subunit non-ATPase 1 (Psmd1), proteasome subunit β 4 (Psmb4), and ubiquitin carboxyl-terminal hydrolase 14 (Usp14), which are related to the proteasome activity; GSTM3 and PRDX1, which encode for the antioxidant enzymes glutathione *S*-transferase mu 3 (Gstm3) and peroxiredoxin 1 (Prdx1); and PKM1 and PKM2, which encode for the isoforms 1 and 2 of the glycolytic enzyme pyruvate kinase (Pkm). As shown in [Figure 7](#ijms-19-02329-f007){ref-type="fig"}, except for Gstm3, whose expression was not modulated by oleocanthal in the presence of H~2~O~2~, all the other genes were up- or down-regulated in agreement with data reported in [Table 2](#ijms-19-02329-t002){ref-type="table"}.

2.6. Role of Oleocanthal in the Modulation of the Ubiquitin--Proteasome System {#sec2dot6-ijms-19-02329}
------------------------------------------------------------------------------

Proteomic and RT-PCR results demonstrated that oleocanthal in the presence of peroxide is able to up-regulate two proteasomal subunits with respect to H~2~O~2~, suggesting its positive role in the degradation of misfolded and oxidized proteins; on the other hand, it up-regulates the expression of the de-ubiquitinating enzyme Usp14 that reduces the number of proteins conveyed to the proteasome. To better investigate this conflicting point, we studied the effect of oleocanthal on these three proteins in the absence of oxidative stress by RT-PCR ([Figure 8](#ijms-19-02329-f008){ref-type="fig"}). Interestingly, in the absence of oxidative stress, oleocanthal up-regulated proteasome subunits Psmb4 and Psmd1 but did not influence Usp14 expression.

2.7. Involvement of HSP90 in Oleocanthal Protection against Oxidative Stress {#sec2dot7-ijms-19-02329}
----------------------------------------------------------------------------

As our proteomic and transcriptional data showed a marked and significant up-regulation of Hsp90α and β by oleocanthal in the presence of H~2~O~2~ with respect to H~2~O~2~ alone, we decided to investigate the role of these heat shock proteins in the observed oleocanthal protection against peroxide. A strict correlation between Akt activity and Hsp90 has been demonstrated \[[@B33-ijms-19-02329]\], so we studied the effect of oleocanthal treatment on both Akt activation (phosphorylation) ([Figure 9](#ijms-19-02329-f009){ref-type="fig"}) and Hsp90α and β expression ([Figure 10](#ijms-19-02329-f010){ref-type="fig"}) in the absence/presence of wortmannin, which affects various signal transduction cascades by inhibiting phosphatidylinositol-3-kinases (PI3Ks), thereby blocking Akt phosphorylation. Interestingly, oleocanthal induced a strong activation of Akt ([Figure 9](#ijms-19-02329-f009){ref-type="fig"}). As expected, in the presence of wortmannin the phosphorylated form of Akt was quite undetectable. Oleocanthal treatment was able to significantly up-regulate both Hsp90 isoforms; meanwhile, wortmannin completely abrogated the up-regulation induced by oleocanthal, maintaining Hsp90α and β levels comparable to those in control cells. In order to clarify the involvement of these heat shock proteins in oleocanthal protection against oxidative stress, SH-SY5Y cells were treated with oleocanthal in the absence/presence of wortmannin and exposed to H~2~O~2~; cell viability was evaluated by MTT assay ([Figure 11](#ijms-19-02329-f011){ref-type="fig"}). Interestingly, in the presence of wortmannin, cell viability of oleocanthal-treated cells was comparable to that of H~2~O~2~-treated cells, suggesting that Hsp90 and/or Akt are essential to conferring neuroprotection against peroxide.

3. Discussion {#sec3-ijms-19-02329}
=============

In this study, we demonstrated that oleocanthal significantly protects differentiated human neuroblastoma SH-SY5Y cell line from oxidative stress induced by H~2~O~2~. In particular, oleocanthal reduces intracellular ROS levels and increases endogenous GSH levels. To further elucidate the mechanisms behind oleocanthal's neuroprotective activity we used proteomic analysis that revealed an involvement of the ubiquitin--proteasome system, heat shock proteins, pyruvate kinases, and peroxiredoxin 1. Proteomic data were validated by real-time PCR analysis in order to have a complementary and wider vision of oleocanthal effect on both gene and protein expression. Since the levels of transcription of the selected genes were similar to their translation, we considered the comparable change in mRNA levels as a validation of proteomic data. A fundamental issue in the study of nutraceutical compounds is their bioavailability. The pharmacokinetics and bioavailability of oleocanthal have been poorly investigated. Under simulated gastric acid conditions, it has been shown that oleocanthal is stable in acidic conditions at 37 °C and almost half of the oleocanthal diffused from the oil phase into the aqueous solution \[[@B34-ijms-19-02329]\]. Only one study has investigated the bioavailability of oleocanthal by identifying oleocanthal and its metabolites in urines, demonstrating oleocanthal metabolism in the human body \[[@B35-ijms-19-02329]\]. Oleocanthal is mainly metabolized through phase I metabolism, like hydroxylation, hydrogenation, and hydration. Some of the hydrogenated oleocanthal metabolites are further metabolized through phase II metabolism \[[@B35-ijms-19-02329]\]. Even if no studies directly examined the blood--brain barrier (BBB) permeability of oleocanthal, different studies indirectly demonstrated its ability to reach the brain. In particular, Qosa et al. reported a decreased amyloid load in the hippocampus of TgSwDI mice after oleocanthal treatment \[[@B21-ijms-19-02329]\]; meanwhile, in C57BL/6 mice, Abuznait et al. demonstrated that oleocanthal induces P-gp and LRP1, which are responsible for Aβ clearance across the BBB, and increases Aβ degradation by up-regulating Aβ-degrading enzymes \[[@B25-ijms-19-02329]\], strongly suggesting its ability to reach the brain.

The ubiquitin--proteasome system is the main proteolytic complex responsible for the removal of misfolded and damaged intracellular proteins, often produced upon oxidative stress \[[@B36-ijms-19-02329]\]. The proteasome is a non-lysosomal threonine protease \[[@B37-ijms-19-02329]\] that degrades both normal and damaged proteins into short peptides by the internal protease activities \[[@B38-ijms-19-02329],[@B39-ijms-19-02329]\]. It has been observed that the impairment of the ubiquitin--proteasome system is implicated in the pathogenesis of many neurodegenerative diseases \[[@B40-ijms-19-02329]\] like Alzheimer's disease, Parkinson's disease, Lewy body dementia, Pick disease, frontotemporal dementia, and Huntington's disease (HD) \[[@B41-ijms-19-02329]\]. On these bases, the induction of the proteasome system has been emerging as a therapeutic target to counteract these diseases. To our best knowledge, no studies have explored the effect of oleocanthal on the ubiquitin--proteasome system upon oxidative stress. Interestingly, our proteomic data, obtained in the presence of oxidative stress, indicate the up-regulation of two proteasome subunits, namely, the 26S proteasome non-ATPase regulatory subunit and the proteasome subunit β type-4, and the up-regulation of the ubiquitin carboxyl-terminal hydrolases 14 (Usp14). As Usp14 negatively regulates proteasome activity by ubiquitin chain disassembly as well as by a noncatalytic mechanism \[[@B42-ijms-19-02329]\], oleocanthal, in the presence of oxidative stress, has two opposite effects: on one side, it up-regulates the proteasome and, on the other side, it up-regulates Usp14, abrogating the suggested enhancement of the proteasome activity. For this reason, we examined the effect of oleocanthal in the absence of oxidative stress by real-time PCR. Intriguingly, in normal conditions, oleocanthal is able to induce proteasome activity as it up-regulates proteasome subunits Psmd1 and Psmb4 and does not affect Usp14 expression, suggesting that oleocanthal could have a role in the degradation of misfolded proteins rather than in the degradation of oxidized ones. Our observations are in agreement with different studies that demonstrated that oleocanthal counteracts neurodegenerative diseases by enhancing the clearance of misfolded proteins like amyloid-β, phosphorylated tau, and α-synuclein \[[@B27-ijms-19-02329],[@B43-ijms-19-02329],[@B44-ijms-19-02329]\].

Hsp90 is a chaperone protein important for maintaining stability, maturation, and signaling of Hsp90 client proteins \[[@B45-ijms-19-02329]\]. It has been demonstrated that Hsp90 maintains cell proliferation and cell survival by different mechanisms. Hsp90 may inhibit apoptosis by binding to apoptotic peptidase-activating factor 1, resulting in the prevention of apoptosome formation, caspase activation, and apoptotic cell death \[[@B46-ijms-19-02329]\]. In addition, Taiyab et al. showed that inhibition of Hsp90 results in ER stress-induced apoptosis in rat histiocytoma \[[@B47-ijms-19-02329]\]. A strict correlation between Hsp90 and Akt has been demonstrated \[[@B33-ijms-19-02329]\], as the inhibition of the binding of Akt to Hsp90 inactivates Akt and makes cells more susceptible to apoptosis-inducing stimuli \[[@B48-ijms-19-02329]\]. Interestingly, Xie et al. observed that the inhibition of Akt activity led to a reduction of Hsp90 level, suggesting that Akt activation can elevate Hsp90 protein levels \[[@B49-ijms-19-02329]\]. Our data demonstrated that oleocanthal, upon oxidative stress, is able to up-regulate Hsp90. As Hsp90 acts with Akt, we also evaluated the effect of oleocanthal treatment on Akt activation (phosphorylation). As expected, we measured a strong and significative activation of Akt. Moreover, Akt inhibition by wortmannin led to the inhibition of the up-regulation of Hsp90 induced by oleocanthal, in agreement with the previous observation by Xie et al. Of note, the fact that wortmannin totally abrogated oleocanthal protection against oxidative stress suggests a fundamental role of Akt and/or Hsp90 in the protective mechanisms elicited by oleocanthal against oxidative stress in SH-SY5Y neuronal cells. As wortmannin can affect other signaling cascades apart from Akt, we could not exclude that oleocanthal regulates neuroprotective effects through other signaling pathways. Further studies are necessary to fully elucidate this aspect.

Our proteomic and expression data indicated a significative up-regulation of Pkm1 and Pkm2 by oleocanthal in the presence of oxidative stress. Pyruvate kinase, catalyzing the final rate-limiting step in glycolysis, is a crucial enzyme for glucose metabolism and energy production in the brain. Elevated levels of pyruvate kinase have been suggested to be protective in neurodegeneration as decreased aerobic glycolysis in the brain leads to a loss of cell survival mechanisms that counter pathogenic processes underlying neurodegeneration \[[@B50-ijms-19-02329]\]. Moreover, Luo et al. demonstrated that Pkm hinders the Aβ fibrillation and reduces the toxicity of Aβ aggregates in SH-SY5Y cells, suggesting that Pkm interferes with the stability of the Aβ oligomer by hydrophobic and hydrophilic interactions of its surface \[[@B51-ijms-19-02329]\].

Oleocanthal also induced a strong up-regulation of the antioxidant enzyme Prdx1 in the presence of H~2~O~2~, as indicated by our proteomic and expression results. Peroxiredoxins play an important role in cell proliferation, redox signaling, differentiation, and gene expression \[[@B52-ijms-19-02329],[@B53-ijms-19-02329]\]. In particular, Prdx1 eliminates hydrogen peroxide produced during cellular metabolism \[[@B54-ijms-19-02329]\] and participates in cell survival by enhancing the expression of the pro-survival factor protein kinase B (PKB) \[[@B55-ijms-19-02329]\]. The role of Prdx1 in AD has been recently highlighted by Majd et al. who observed reduced levels of Prdx1 and 2 in postmortem brains of AD \[[@B56-ijms-19-02329]\]; meanwhile, Schreibelt et al. analyzed the functional role of Prdx1 using a brain endothelial cell line overexpressing Prdx1 and showed that enhanced Prdx1 expression in brain endothelial cells increased BBB integrity and reduced monocyte adhesion to and migration across a brain endothelial cell layer \[[@B57-ijms-19-02329]\].

Focusing on proteomic results, the quantitative two-dimensional analysis showed that the insult induced by peroxide induced a significantly different expression of four Prdx in the human neuroblastoma SH-SY5Y cell line. Interestingly, two near spots, different for the pI value and for level of expression, were detected for PRDX1, 2, and 6 in our samples, suggesting the presence of post-translational modification. Post-translational modification and intracellular protein--protein interactions have the potential to influence Prdx catalytic activity and susceptibility to hyperoxidation \[[@B58-ijms-19-02329]\]. We found for all three Prdx an increase of expression of more acidic spots and a significant reduction of more basic spots in the H~2~O~2~ sample with respect to the control. The protective effect of oleocanthal takes place by way of an increase of more acidic spots of Prx1. The nature of this modification needs to be investigated and underlines a mechanism of control of protein activity.

Finally, all proteins found differentially expressed from a comparison of oleocanthal + H~2~O~2~ vs. H~2~O~2~ were analyzed by IPA to explore in depth the network, functions, and molecules (e.g., upstream regulators) that could play a role in the protection induced by oleocanthal. The molecular functions defined by our differentially expressed proteins were well arranged in protein synthesis, cell death and survival, protein degradation, and cellular function and maintenance. On the other hand, the up-regulation of heat shock protein and proteasome members in addition to ubiquitin enzymes and pyruvate kinase concurred to predict cellular viability and vitality ([Figure 12](#ijms-19-02329-f012){ref-type="fig"}). As concerns upstream regulators, intriguing results arose from the IPA analysis. Along the list of noteworthy potential activated or inhibited upstreams were NFE2L2, HSF1, and ATF7.

NFE2L2, which encodes for the transcription factor Nrf2, is important for the coordinated up-regulation of genes in response to oxidative stress. Very recent studies showed neuroprotective actions \[[@B59-ijms-19-02329],[@B60-ijms-19-02329]\] through the activation of Akt/Nrf2/antioxidant enzymes in neuronal cells. On the other hand, the significant up-regulation of the active form of Akt that we found in our results agrees with an activation state of Nrf2.

HSF1 works as a stress-inducible and DNA-binding transcription factor that plays a central role in the transcriptional activation of the heat shock response, leading to the expression of a large number of chaperone heat shock proteins. A central role of HSF1 in synaptic fidelity and memory consolidation has been recently suggested by Hooper and coworkers \[[@B61-ijms-19-02329]\] who showed that the activation of HSF1 alone augmented vesicle transport and synaptic scaffolding proteins. Meanwhile, HSF1 agonists can improve cognitive function in dementia models and activation of neuroprotective signaling pathways. Finally, HSF1 protected neurons from death caused by accumulation of misfolded proteins. This neuroprotection result was abrogated by inhibition of classical deacetylases such as SIRT1 \[[@B62-ijms-19-02329]\].

As concerns ATG7 (autophagy-related 7), a predicted inhibition was advanced by IPA analysis. ATG7 is an E1-like activating enzyme involved in the 2-ubiquitin-like systems required for cytoplasm-to-vacuole transport and autophagy. Recent findings reveal that selective neuronal deletion of ATG7 is strongly protective against neuronal death and overall brain hypoxic--ischemic injury \[[@B63-ijms-19-02329]\].

Overall, our results, combined with IPA analysis, suggest that the major part of protein targets of oleocanthal in response to peroxide insult belongs to the proteostasis network including proteasome, ubiquitin, and chaperone proteins which move to restore equilibrium between protein synthesis, folding, trafficking, secretion, and degradation in different cell compartments. Moreover, our findings add new evidence on the effects of oleocanthal on heat shock protein 90, Pkm1 and 2, and Prdx1.

4. Materials and Methods {#sec4-ijms-19-02329}
========================

4.1. Materials {#sec4dot1-ijms-19-02329}
--------------

MTT, DCFH-DA, H~2~O~2~, dimethyl sulfoxide (DMSO), MCB, Phosphate-Buffered Saline (PBS), bovine serum albumin (BSA) Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, wortmannin, primers listed in [Table 5](#ijms-19-02329-t005){ref-type="table"}, mammalian protease inhibitor mixture, radioimmunoprecipitation assay (RIPA) buffer, all trans retinoic acid (RA), and all other chemicals of the highest analytical grade were purchased from Sigma Chemical (St. Louis, MO, USA). PhosSTOP was purchased from Roche Diagnostics (Mannheim, Germany).

4.2. Cell Culture and Treatments {#sec4dot2-ijms-19-02329}
--------------------------------

The SH-SY5Y human neuroblastoma cell line was obtained from Sigma-Aldrich (Milan, Italy). Cells were grown in DMEM supplemented with 10% (*v*/*v*) of FBS, 2 mM glutamine, 50 U/mL of penicillin, and 50 μg/mL of streptomycin and maintained at 37 °C in a humidified incubator with 5% CO~2~ as previously reported \[[@B64-ijms-19-02329]\]. Cell differentiation was induced, reducing serum levels of the medium to 1% with 10 µM of RA for seven days prior to treatments. Differentiated SH-SY5Y were treated with oleocanthal for 1 or 24 h. Oleocanthal was dissolved in DMSO and kept at −20 °C until use. The control group was treated with an equivalent volume of the vehicle alone. Oxidative stress was induced by exposing cells to 700 µM H~2~O~2~.

4.3. MTT Assay {#sec4dot3-ijms-19-02329}
--------------

Cells were treated with different concentrations of oleocanthal (1--10 µM) for 24 h prior to induction of oxidative stress. Cell viability was evaluated by measuring formazan formation as previously reported \[[@B64-ijms-19-02329],[@B65-ijms-19-02329]\]. Briefly, after treatments, cells were incubated with 0.5 mg/mL of MTT solution for 1 h at 37 °C. After incubation, MTT was removed and 100 µL of DMSO were added, and the absorbance was recorded at λ = 595 nm using a microplate spectrophotometer (VICTOR3 V Multilabel Counter; PerkinElmer, Wellesley, MA, USA).

4.4. Intracellular ROS Production Assay {#sec4dot4-ijms-19-02329}
---------------------------------------

The production of intracellular reactive oxygen species was evaluated using the fluorescent probe DCFH-DA as reported in \[[@B66-ijms-19-02329]\]. Briefly, differentiated SH-SY5Y were treated with oleocanthal for 24 h and then incubated with 10 µM DCFH-DA in DMEM *w*/*o* FBS for 30 min. After DCFH-DA removal, cells were incubated with H~2~O~2~ for 30 min. Cells were washed with PBS and the fluorescence was measured using 485 nm excitation and 535 nm emission with a microplate spectrofluorometer (VICTOR3 V Multilabel Counter, PerkinElmer, Wellesley, MA, USA).

4.5. Intracellular GSH Levels Assay {#sec4dot5-ijms-19-02329}
-----------------------------------

The levels of reduced glutathione (GSH) were evaluated by a fluorometric assay, using the fluorescent probe MCB \[[@B64-ijms-19-02329],[@B67-ijms-19-02329]\]. Briefly, differentiated SH-SY5Y pretreated with oleocanthal were exposed to H~2~O~2~ for 1 h and incubated with 50 µM MCB in serum-free medium for 30 min at 37 °C. After incubation, cells were washed in PBS and the fluorescence was measured at 355 nm (excitation) and 460 nm (emission) with a microplate spectrofluorometer (VICTOR3 V Multilabel Counter; PerkinElmer, Wellesley, MA, USA).

4.6. RNA Extraction {#sec4dot6-ijms-19-02329}
-------------------

Total RNA was extracted using an RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany), following the manufacturer's protocol. The yield and purity of the RNA were measured using a NanoVue Spectrophotometer (GE Healthcare, Milano, Italy).

4.7. Analysis of mRNA Levels by Reverse Transcriptase Polymerase Chain Reaction {#sec4dot7-ijms-19-02329}
-------------------------------------------------------------------------------

cDNA was obtained by reverse transcribing mRNA starting from 1 μg of total RNA using an iScript cDNA Synthesis Kit (BIO-RAD, Hercules, CA, USA), following the manufacturer's protocol. The subsequent polymerase chain reaction (PCR) was performed in a total volume of 10 μL containing 2.5 μL (12.5 ng) of cDNA, 5 μL SsoAdvanced Universal SYBR Green Supermix (BIO-RAD), and 0.5 μL (500 nM) of each primer. The primers used are reported in [Table 5](#ijms-19-02329-t005){ref-type="table"}; 18S rRNA was used as reference gene.

4.8. Western Blotting {#sec4dot8-ijms-19-02329}
---------------------

After treatments, differentiated SH-SY5Y were collected and homogenized in RIPA buffer with a mammalian protease inhibitor mixture and PhosSTOP. Samples were boiled for 5 min prior to separation on 10% MiniPROTEAN TGX Precast Protein Gels (BIO-RAD, Hercules, CA, USA). The proteins were transferred to a nitrocellulose membrane (Hybond-C; GE Healthcare, Buckinghamshire, UK) in Tris-glycine buffer at 110 V for 90 min. Membranes were then incubated in a blocking buffer containing 5% (*w*/*v*) skimmed milk and incubated with anti-phospho-Akt, anti-Akt (Cell Signaling Technology, Beverly, MA, USA), and anti-β-actin (Sigma-Aldrich), which was used as internal normalizer, overnight at 4 °C on a three-dimensional rocking table. The results were visualized by chemiluminescence using Clarity Western Enhanced Chemiluminescence (ECL) reagent according to the manufacturer's protocol (BIO-RAD). Semiquantitative analysis of specific immuno-labeled bands was performed using ImageLabTM 5.2 Software (BIO-RAD).

4.9. Sample Preparation for Proteomic Analysis {#sec4dot9-ijms-19-02329}
----------------------------------------------

For proteomic analysis, differentiated SH-SY5Y cells (about 7 × 10^5^ cells) were treated with oleocanthal or H~2~O~2~, or with both for 24 h as described above. At the end of treatment, cells were collected and washed with PBS. After centrifugation (1000× *g* for 5 min), the resulting pellets were immediately frozen and stored at −80 °C until use. For proteomic studies, each condition was performed in triplicate.

4.10. 2DE Analysis {#sec4dot10-ijms-19-02329}
------------------

Cell pellets were resuspended in rehydration solution \[[@B68-ijms-19-02329]\], and protein contents of resulting protein extracts were measured with an RC-DC Protein Assay from Bio-Rad.

2DE was carried out as previously described \[[@B69-ijms-19-02329]\]. Briefly, 200 µg of proteins were filled up to 450 μl in rehydration solution. Immobiline Dry-Strips (GE Health Care Europe; Uppsala, Sweden); 18 cm, nonlinear gradient pH 3--10) were rehydrated overnight in the sample and then transferred to the Ettan IPGphor Cup Loading Manifold (GE Healthcare) for isoelectrofocusing (IEF). The second dimension (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis; SDS-PAGE) was carried out by transferring the proteins to 12% polyacrylamide, running at 16 mA per gel and 10 °C for about 16 h, using the Protean^®^ Plus Dodeca Cell (Bio-Rad). The gels were stained with Ruthenium II tris (bathophenanthroline disulfonate) tetrasodium salt (SunaTech Inc., Suzhou, China) (RuBP). ImageQuant LAS4010 (GE Health Care) was used for the acquisition of images. The analysis of images was performed using Same Spot (v4.1, TotalLab, Newcastle Upon Tyne, UK) software. The spot volume ratios between the four different conditions were calculated using the average spot normalized volume of the three biological replicates performed in duplicate. The software included statistical analysis calculations.

4.11. 2DE Statistical Analysis {#sec4dot11-ijms-19-02329}
------------------------------

A comparison among the different treatments was performed. The significance of the differences of normalized volume for each spot was calculated by the software Same Spot including the analysis of variance (ANOVA test). The protein spots of interest were cut out from the gel and identified by LC-MS analysis.

4.12. Spot Digestion and Protein Identification {#sec4dot12-ijms-19-02329}
-----------------------------------------------

The gel pieces were washed twice with the wash buffer (25 mM NH~4~HCO~3~ in 50% acetonitrile (ACN)). Afterwards, proteins were reduced with 10 mM ditiothreitol (DTT) (45 min, 56 °C), and alkylated with 55 mM iodoacetamide (IAA) (30 min, RT, in the dark). After two washes with the wash buffer, spots were completely dried in a centrivap vacuum centrifuge. The dried pieces of gel were rehydrated for 30 min at 4 °C in 30 μL of trypsin porcine (Promega, Madison, WI, USA) solution (3 ng/μL in 100 mM NH~4~HCO~3~) and then incubated at 37 °C overnight. The reaction was stopped by adding 10% trifluoroacetic acid (TFA). Samples were analyzed by LC-MS as described \[[@B70-ijms-19-02329]\] using a shorter chromatographic gradient and in autoMS mode. Each digested spot sample was analyzed by LC-MS/MS using a Proxeon EASY-nLCII (Thermo Fisher Scientific, Milan, Italy) chromatographic system coupled to a Maxis HD UHR-TOF (Bruker Daltonics GmbH, Bremen, Germany) mass spectrometer. Peptides were loaded on the EASY-Column TM C18 trapping column (2 cm L., 100 µm I.D, 5 µm ps, Thermo Fisher Scientific), and subsequently separated on an Acclaim PepMap100 C18 (75 µm I.D., 25 cm L, 5 µm ps, Thermo Fisher Scientific) nanoscale chromatographic column. The flow rate was set to 300 nL/min and the gradient was from 2% to 20% of B in 12 min followed by 20 to 45% in 9 min and from 45% to 90% in 2 min (total run time 35 min). Mobile phase A was 0.1% formic acid in H~2~O and mobile phase B was 0.1% formic acid in acetonitrile. The mass spectrometer, typically providing a 60,000 full width at half maximum (FMHW) resolution throughout the mass range, was equipped with a nanoESI spray source. The mass spectrometer was operated in Data Dependent Acquisition mode (DDA), using N~2~ as the collision gas for collision-induced dissociation (CID) fragmentation. Precursors in the range 400 to 2200 *m*/*z* (excluding 1220.0--1224.5 *m*/*z*) with a preferred charge state +2 to +5 and absolute intensity above 4706 counts were selected for fragmentation in a fixed cycle time of 3 s. After two spectra, the precursors were actively excluded from selection for 36 s. Isolation width and collision energy for MS/MS fragmentation were set according to the mass and charge state of the precursor ions (from 2+ to 5+ and from 21 to 55 eV). In-source reference lock mass (1221.9906 *m*/*z*) was acquired online throughout runs.

The raw data were processed using PEAKS Studio v7.5 software (Bioinformatic Solutions Inc., Waterloo, ON, Canada) using the function "correct precursor only". The mass lists were searched against the nextprot database including isoforms (version as of June 2017; 42,151 entries) using 10 ppm and 0.05 Da as the highest error tolerances for parent and fragment ions, respectively. Carbamidomethylation of cysteines was selected as fixed modification and oxidation of methionines and deamidation of asparagine and glutamine as variable modifications allowing 2 missed cleavages.

4.13. Network Analysis {#sec4dot13-ijms-19-02329}
----------------------

Proteins differentially expressed obtained from the oleocanthal + H~2~O~2~ vs. H~2~O~2~ comparison were functionally analyzed through the use of QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, CA, USA, [www.qiagen.com/ingenuity](www.qiagen.com/ingenuity)) with the aim to determine the predominant canonical pathways and interaction network involved. Swiss-Prot accession numbers and official gene symbols were inserted into the software along with corresponding comparison ratios and *p* values. The network proteins associated with biological functions and/or diseases in the Ingenuity Pathways Knowledge Base were considered for the analysis. The created networks describe functional relationships among proteins based on known associations in the literature. A comparison of the different analyses was created and the upstream regulators whose activity appears to change in a significant manner according to the activation *z*-score value were shown. Finally, to generate plausible causal networks which explain observed expression changes, hidden connections in upstream regulators were also uncovered.
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![Viability of differentiated SH-SY5Y treated with oleocanthal in the absence/presence of H~2~O~2~. (**a**) Cells were treated with oleocanthal (1--10 µM) for 24 h, (**b**) cells were treated with peroxide (0.1--1 mM), or (**c**) cells were treated with oleocanthal (1--10 µM) and after 24 h exposed to 700 µM H~2~O~2~ for 1 h; cell viability was measured by MTT assay. Each bar represents means ± SEM of at least four independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni's test. \* *p* \< 0.05 with respect to control (CTRL); ° *p* \< 0.05 with respect to H~2~O~2~.](ijms-19-02329-g001){#ijms-19-02329-f001}

![Antioxidant activity of oleocanthal against H~2~O~2~ in differentiated SH-SY5Y cells. Cells were treated with 10 μM oleocanthal and after 24 h were exposed to H~2~O~2~. Intracellular reactive oxygen species (ROS) levels were measured with the peroxide-sensitive probe DCFH-DA as reported in Materials and Methods. Data are expressed as a percentage with respect to H~2~O~2~-treated cells. Each bar represents mean ± SEM of at least four independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. \* *p* \< 0.05 with respect to CTRL; ° *p* \< 0.05 with respect to H~2~O~2~.](ijms-19-02329-g002){#ijms-19-02329-f002}

![Effect of oleocanthal on GSH levels in differentiated SH-SY5Y cells. Cells were treated with 10 μM oleocanthal and after 24 h were exposed to peroxide. GSH levels were measured using the fluorescence probe MCB as reported in Materials and Methods. Each bar represents the mean ± SEM of four independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. \* *p* \< 0.05 with respect to CTRL; ° *p* \< 0.05 with respect to H~2~O~2~.](ijms-19-02329-g003){#ijms-19-02329-f003}

![Representative 2D gel map of differentiated SH-SY5Y human neuroblastoma cellular protein extracts. (**A**) Control cells; (**B**) H~2~O~2~-treated cells; (**C**) Oleocanthal + H~2~O~2~ treated cells. Proteins were separated in a 3--10 nonlinear gradient. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed at 12% of acrylamide.](ijms-19-02329-g004){#ijms-19-02329-f004}

![Protein expression profiling of oleocanthal + H~2~O~2~ vs. H~2~O~2~. Scatter plot of fold change (*x* axis), against log *p*-value (*y* axis) of all quantified proteins. Up- and Down-regulated proteins are colored red and green, respectively. Dotted line indicates the threshold of significance.](ijms-19-02329-g005){#ijms-19-02329-f005}

![Functional Network. Proteins differentially expressed resulting from the oleocanthal + H~2~O~2~ vs. H~2~O~2~ comparison were functionally analyzed through the use of QIAGEN's Ingenuity Pathway Analysis. Network describes functional relationships among proteins based on known associations in the literature. Solid line: direct interaction; dotted line: indirect interaction. \* This protein has been identified in many spots.](ijms-19-02329-g006){#ijms-19-02329-f006}

![Transcriptional validation of proteomic data. Differentiated SH-SY5Y were pretreated with 10 µM oleocanthal for 24 h and then exposed to 700 µM H~2~O~2~ for 1 h. Total RNA was isolated, and the mRNA level of target genes was quantified using RT-PCR normalized to 18S rRNA reference gene as reported in Materials and Methods. Triplicate reactions were performed for each experiment. Each bar represents the mean ± SEM of three independent experiments. Data were analyzed by Student's *t-*test. \* *p* \< 0.05 with respect to H~2~O~2~.](ijms-19-02329-g007){#ijms-19-02329-f007}

![Effect of oleocanthal on the ubiquitin--proteasome system in the absence of H~2~O~2~. Differentiated SH-SY5Y were treated with 10 µM oleocanthal for 24 h. Total RNA was isolated, and the mRNA level of target genes was quantified using RT-PCR normalized to 18S rRNA reference gene as reported in Materials and Methods. Triplicate reactions were performed for each experiment. Each bar represents the mean ± SEM of three independent experiments. Data were analyzed by Student's *t-*test. \* *p* \< 0.05 with respect to CTRL.](ijms-19-02329-g008){#ijms-19-02329-f008}

![Akt kinase activation following oleocanthal treatment in the presence of PI3K-specific inhibitor. Differentiated SH-SY5Y were exposed to 100 nM wortmannin 1 h before 10 µM oleocanthal treatment for 1 h. Proteins were separated by SDS-PAGE and immunoblotted for total and phosphorylated form of Akt as reported in Materials and Methods. Each bar represents the mean ± SEM of three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. \* *p* \< 0.05 with respect to CTRL; ^§^ *p* \< 0.05 with respect to oleocanthal.](ijms-19-02329-g009){#ijms-19-02329-f009}

![Akt-specific inhibitor wortmannin prevents oleocanthal-induced HSP90s. Differentiated SH-SY5Y were treated with 100 nM wortmannin 1 h before exposure to 10 µM oleocanthal for 24 h. Total RNA was isolated, and the mRNA level of target genes was quantified using RT-PCR normalized to 18S rRNA reference gene as reported in Materials and Methods. Triplicate reactions were performed for each experiment. Each bar represents the mean ± SEM of three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. \* *p* \< 0.05 with respect to CTRL; ^§^ *p* \< 0.05 with respect to oleocanthal; ^\#^ *p* \< 0.05 with respect to oleocanthal + wortmannin.](ijms-19-02329-g010){#ijms-19-02329-f010}

![Effect of Akt inhibitor wortmannin on H~2~O~2~-induced injury in differentiated SH-SY5Y. Cells were treated with 10 µM oleocanthal for 24 h in absence/presence of 100 nM wortmannin prior to peroxide exposure, then cell viability was assessed with MTT assay. Each bar represents the mean ± SEM of three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferroni's test. \* *p* \< 0.05 with respect to CTRL; ° *p* \< 0.05 with respect to H~2~O~2;~ ^§^ *p* \< 0.05 with respect to oleocanthal.](ijms-19-02329-g011){#ijms-19-02329-f011}

![Downstream functions. Predicted activated functions based on up- (red) and down- (green) regulated proteins. Arrows predict a direct (orange) or indirect (grey) action on cell function. T bar predicts an inhibition on cell function. \* This protein has been identified in many spots.](ijms-19-02329-g012){#ijms-19-02329-f012}

ijms-19-02329-t001_Table 1

###### 

MS/MS data of protein spots differentially expressed grouped by functional class. MW, molecular weight; pI, isoelectric point; th, theoretical.

  \# Spot                                                      Protein Name                                                             Gene       ID       Peptide (n)   Unique   Coverage (%)   MW (th)   pI (th)
  ------------------------------------------------------------ ------------------------------------------------------------------------ ---------- -------- ------------- -------- -------------- --------- ---------
  Metabolism                                                                                                                                                                                                
  381                                                          Guanosine 5′-monophosphate synthase (glutamine-hydrolyzing)              GMPS       P49915   32            32       52             76,716    6.42
  521                                                          Pyruvate kinase PKM                                                      PKM        P14618   36            6        59             57,937    7.96
  559                                                          Amidophosphoribosyltransferase                                           PPAT       Q06203   4             4        10             57,398    6.3
  693                                                          Gamma-enolase                                                            ENO2       P09104   13            13       46             47,269    4.91
  856                                                          Cytosolic acyl coenzyme A thioester hydrolase                            ACOT7      O00154   3             3        14             27,041    6.51
  876                                                          Alcohol dehydrogenase (NADP(+))                                          AKR1A1     P14550   14            14       50             36,573    6.32
  939                                                          Malate dehydrogenase, cytoplasmic                                        MDH1       P40925   7             7        32             36,426    6.91
  950                                                          ADP-sugar pyrophosphatase                                                NUDT5      Q9UKK9   6             6        26             24,328    4.87
  1069                                                         Enoyl-CoA hydratase, mitochondrial                                       ECHS1      P30084   13            13       43             31,387    8.34
  1076                                                         NADH:ubiquinone oxidoreductase iron-sulfur protein 3, mitocondrial       NDUFS3     O75489   8             8        32             30,242    6.98
  1098                                                         Triosephosphate isomerase                                                TPI1       P60174   12            12       57             26,669    6.45
  2010                                                         Phosphoglycerate kinase 1                                                PGK1       P00558   41            35       72             44,615    8.3
  2010                                                         Isocitrate dehydrogenasemitochondrial isoform2                           IDH2       P48735   25            25       53             45,180    7.63
  Protein synthesis, modification secretion folding                                                                                                                                                         
  296                                                          Acylamino-acid-releasing enzyme                                          APEH       P13798   15            15       24             81,225    5.29
  708                                                          Adenosylhomocysteinase                                                   AHCY       P23526   18            18       37             47,716    5.92
  916                                                          Small glutamine-rich tetratricopeptide repeat-containing protein alpha   SGTA       O43765   8             8        27             34,063    4.79
  940                                                          Ubiquitin thioesterase OTUB1                                             OTUB1      Q96FW1   5             5        23             31,284    4.85
  1230                                                         Protein DJ-1                                                             PARK7      Q99497   11            11       49             19,891    6.32
  1812                                                         Platelet-activating factor acetylhydrolase IB subunit gamma              PAFAH1B3   Q15102   6             6        27             25,734    6.33
  Protein degradation                                                                                                                                                                                       
  498                                                          Ubiquitin carboxyl-terminal hydrolase 14                                 USP14      P54578   13            13       35             52,386    5.61
  995                                                          Proteasome activator complex subunit 3                                   PSME3      P61289   10            10       39             29,506    5.69
  1111                                                         Ubiquitin carboxyl-terminal hydrolase isozyme L1                         UCHL1      P09936   29            29       81             24,824    5.33
  Cytoskeleton, vesicle motility, transport, vesicle release                                                                                                                                                
  430                                                          Dihydropyrimidinase-related protein 3                                    DPYSL3     Q14195   29            24       57             73,911    5.94
  436                                                          Dihydropyrimidinase-related protein 3                                    DPYSL3     Q14195   30            30       58             73,911    5.94
  441                                                          Dihydropyrimidinase-related protein 3                                    DPYSL3     Q14195   29            24       58             73,911    5.94
  1079                                                         Ran-specific GTPase-activating protein                                   RANBP1     P43487   9             9        50             23,310    5.19
  1425                                                         Cofilin-1                                                                CFL1       P23528   8             8        51             18,502    8.22
  1743                                                         F-actin-capping protein subunit β                                        CAPZB      P47756   17            17       56             30,629    5.69
  RNA synthesis/metabolism                                                                                                                                                                                  
  590                                                          ATP-dependent RNA helicase DDX39A                                        DDX39A     O00148   16            16       35             49,130    5.46
  621                                                          Spliceosome RNA helicase DDX39B                                          DDX39B     Q13838   18            18       39             48,991    5.44
  624                                                          Heterogeneous nuclear ribonucleoprotein H                                HNRNPH1    P31943   25            13       55             49,229    5.89
  836                                                          Heterogeneous nuclear ribonucleoprotein A3                               HNRNPA3    P51991   24            23       49             39,595    9.1
  876                                                          Heterogeneous nuclear ribonucleoprotein H3                               HNRNPH3    P31942   12            12       58             36,926    6.37
  915                                                          Heterogeneous nuclear ribonucleoprotein H3                               HNRNPH3    P31942   8             8        40             35,239    6.36
  1735                                                         Heterogeneous nuclear ribonucleoprotein A1                               HNRNPA1    P09651   15            11       63             29,386    9.19
  Chromatin remodeling and histone                                                                                                                                                                          
  498                                                          Poly(U)-binding-splicing factor PUF60 isoforma1                          PUF60      Q9UHX1   10            10       28             59,875    5.19
  Stress response                                                                                                                                                                                           
  181                                                          26S proteasome non-ATPase regulatory subunit 1                           PSMD1      Q99460   16            16       27             10,2258   5.14
  334                                                          Heat shock protein HSP 90-α                                              HSP90AA1   P07900   12            6        19             84,660    4.94
  335                                                          Heat shock protein HSP 90-β                                              HSP90AB1   P08238   15            8        24             83,264    4.96
  498                                                          60 kDa heat shock protein. mitochondrial                                 HSPD1      P10809   31            31       54             61,055    5.7
  506                                                          60 kDa heat shock protein. mitochondrial                                 HSPD1      P10809   54            54       73             61,055    5.7
  1153                                                         60 kDa heat shock protein. mitochondrial                                 HSPD1      P10809   4             4                       61,055    5.7
  701                                                          DnaJ homolog subfamily A member 2                                        DNAJA2     O60884   15            15       35             45,746    6.06
  995                                                          Proteasome activator complex subunit 3                                   PSME3      P61289   10            10       39             29,506    5.69
  1087                                                         Peroxiredoxin-6                                                          PRDX6      P30041   21            21       65             25,035    6
  1090                                                         Peroxiredoxin-6                                                          PRDX6      P30041   20            20       67             25,035    6
  1122                                                         Heat shock protein β-1                                                   HSPB1      P04792   21            21       77             22,783    5.98
  1253                                                         Peroxiredoxin-2                                                          PRDX2      P32119   30            30       59             21,892    5.66
  1269                                                         Peroxiredoxin-2                                                          PRDX2      P32119   20            20       59             21,892    5.66
  1725                                                         Peroxiredoxin-4                                                          PRDX4      Q13162   4             4        17             30,540    5.86
  1731                                                         Peroxiredoxin-1                                                          PRDX1      Q06830   21            21       72             22,110    8.27
  1736                                                         Peroxiredoxin-1                                                          PRDX1      Q06830   17            17       72             22,110    8.27
  1741                                                         Thioredoxin-dependent peroxide reductase. mitochondrial                  PRDX3      P30048   11            11       46             27,693    7.68
  1743                                                         F-actin-capping protein subunit β                                        CAPZB      P47756   17            17       56             30,629    5.69
  Miscellaneous                                                                                                                                                                                             
  498                                                          Ubiquitin carboxyl-terminal hydrolase 14                                 USP14      P54578   13            13       35             52,386    5.61
  715                                                          Programmed cell death protein 2-like                                     PDCD2L     Q9BRP1   3             3        13             39,417    4.71
  826                                                          Guanine nucleotide-binding protein G(i) subunit α-2                      GNAI2      P04899   16            13       50             40,451    5.34
  843                                                          V-type proton ATPase subunit d 1                                         ATP6V0D1   P61421   5             5        20             40,329    4.89
  843                                                          Nucleophosmin                                                            NPM1       P06748   14            14       52             32,575    4.64
  950                                                          Annexin A5                                                               ANXA5      P08758   6             6        18             35,937    4.93
  1153                                                         High mobility group protein B1                                           HMGB1      P09429   4             4        24             24,894    5.6
  1733                                                         Chloride intracellular channel protein 1                                 CLIC1      O00299   16            15       61             26,923    5.09
  1743                                                         N(G).N(G)-dimethylarginine dimethylaminohydrolase 2                      DDAH2      O95865   13            13       54             29,644    5.66
  1767                                                         MICOS complex subunit MIC60                                              IMMT       Q16891   41            41       60             82625     6.15
  1813                                                         28 kDa heat- and acid-stable phosphoprotein                              PDAP1      Q13442   3             3        13             20,630    8.84

ijms-19-02329-t002_Table 2

###### 

List of differentially expressed proteins after comparison between H~2~O~2~ vs. Control (ctrl). ID: SwissProt accession Number; OD: Normalized optical density.

  \# Spot   ID       Gene       Protein Name                                              Ratio (OD) H~2~O~2~/Ctrl   *p*-Value
  --------- -------- ---------- --------------------------------------------------------- -------------------------- ---------------
  181       Q99460   PSMD1      26S proteasome non-ATPase regulatory subunit 1            0.76                       0.026
  335       P08238   HSP90AB1   Heat shock protein HSP 90-beta                            0.67                       0.018
  381       P49915   GMPS       GMP synthase \[glutamine-hydrolyzing\]                    0.75                       0.014
  430       Q14195   DPYSL3     Dihydropyrimidinase-related protein 3                     0.58                       0.002
  436       Q14195   DPYSL3     Dihydropyrimidinase-related protein 3                     0.74                       0.001
  441       Q14195   DPYSL3     Dihydropyrimidinase-related protein 3                     1.56                       0.022
  506       P10809   HSPD1      60 kDa heat shock protein. mitochondrial                  0.83                       0.011
  559       Q06203   PPAT       Amidophosphoribosyltransferase                            0.57                       0.046
  621       Q13838   DDX39B     Spliceosome RNA helicase DDX39B                           0.83                       0.022
  624       P31943   HNRNPH1    Heterogeneous nuclear ribonucleoprotein H                 0.81                       0.039
  701       DNAJA2   O60884     DnaJ homolog subfamily A member 2                         0.77                       0.017
  708       P23526   AHCY       Adenosylhomocysteinase                                    0.82                       0.012
  856       O00154   ACOT7      Cytosolic acyl coenzyme A thioester hydrolase             0.76                       0.036
  876       P14550   AKR1A1     Alcohol dehydrogenase (NADP(+))                           0.69                       0.043
  876       P31942   HNRNPH3    Heterogeneous nuclear ribonucleoprotein H3                                           
  915       P31942   HNRNPH3    Heterogeneous nuclear ribonucleoprotein H3                0.71                       0.026
  939       P40925   MDH1       Malate dehydrogenase. cytoplasmic                         0.68                       0.026
  940       Q96FW1   OTUB1      Ubiquitin thioesterase OTUB1                              0.73                       0.017
  950       P08758   ANXA5      Annexin A5                                                0.78                       0.012
  950       Q9UKK9   NUDT5      ADP-sugar pyrophosphatase                                                            
  1069      P30084   ECHS1      Enoyl-CoA hydratase. mitochondrial                        0.78                       0.023
  1079      P43487   RANBP1     Ran-specific GTPase-activating protein                    0.80                       0.035
  1087      P30041   PRDX6      Peroxiredoxin-6                                           5.84                       0.007
  1090      P30041   PRDX6      Peroxiredoxin-6                                           0.53                       0.032
  1098      P60174   TPI1       Triosephosphate isomerase                                 0.68                       0.004
  1122      P04792   HSPB1      Heat shock protein β-1                                    0.69                       0.015
  1179      P28070   PSMB4      Proteasome subunit β type-4                               0.80                       0.036
  1253      P32119   PRDX2      Peroxiredoxin-2                                           0.17                       4.4 × 10^−7^
  1269      P32119   PRDX2      Peroxiredoxin-2                                           2.27                       3.08 × 10^−5^
  1725      Q13162   PRDX4      Peroxiredoxin-4                                           0.62                       0.016
  1731      Q06830   PRDX1      Peroxiredoxin-1                                           0.33                       4.28 × 10^−6^
  1736      Q06830   PRDX1      Peroxiredoxin-1                                           3.37                       1.37 × 10^−6^
  1741      P30048   PRDX3      Thioredoxin-dependent peroxide reductase mitochondrial    0.48                       0.00041
  1743      P47756   CAPZB      F-actin-capping protein subunit β                         0.80                       0.042
  1743      O95865   DDAH2      N(G).N(G)-dimethylarginine dimethylaminohydrolase 2                                  
  1767      Q16891   IMMT       MICOS complex subunit MIC60                               0.72                       0.021
  1812      Q15102   PAFAH1B3   Platelet-activating factor acetylhydrolase IB subunit γ   0.76                       0.021

ijms-19-02329-t003_Table 3

###### 

List of differentially expressed proteins after comparison between oleocanthal (OC) + H~2~O~2~ vs. H~2~O~2~. ID: SwissProt accession. Number; OD: Normalized optical density.

  \# Spot   ID       Gene       Protein Name                                       Ratio M ± SD (OD) OC + H~2~O~2~/H~2~O~2~   *p*-Value
  --------- -------- ---------- -------------------------------------------------- ------------------------------------------ -----------
  181       Q99460   PSMD1      26S proteasome non-ATPase regulatory subunit 1     1.29                                       0.034
  296       P13798   APEH       Acylamino-acid-releasing enzyme                    1.28                                       0.009
  334       P08238   HSP90AB1   Heat shock protein HSP 90-β                        1.33                                       0.026
  334       P07900   HSP90AA1   Heat shock protein HSP 90-alpha                                                               
  498       P54578   USP14      Ubiquitin carboxyl-terminal hydrolase 14           1.30                                       0.023
  498       Q9UHX1   PUF60      Poly(U)-binding-splicing factor PUF60 isoforma1                                               
  521       P14618   PKM        Pyruvate kinase PKM                                1.35                                       0.035
  590       O00148   DDX39A     ATP-dependent RNA helicase DDX39A                  1.36                                       0.018
  621       Q13838   DDX39B     Spliceosome RNA helicase DDX39B                    1.29                                       0.013
  715       Q9BRP1   PDCD2L     Programmed cell death protein 2-like               0.77                                       0.013
  836       P51991   HNRNPA3    Heterogeneous nuclear ribonucleoprotein A3         0.64                                       0.023
  843       P61421   ATP6V0D1   V-type proton ATPase subunit d 1                   0.64                                       0.019
  843       P06748   NPM1       Nucleophosmin                                                                                 
  940       Q96FW1   OTUB1      Ubiquitin thioesterase OTUB1                       1.45                                       0.036
  1109      P21266   GSTM3      Glutathione *S*-transferase Mu 3                   1.23                                       0.036
  1111      P09936   UCHL1      Ubiquitin carboxyl-terminal hydrolase isozyme L1   1.25                                       0.002
  1153      P09429   HMGB1      High mobility group protein B1                     0.43                                       0.049
  1179      P28070   PSMB4      Proteasome subunit β type-4                        1.30                                       0.024
  1736      Q06830   PRDX1      Peroxiredoxin-1                                    1.21                                       0.029
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###### 

Master regulators predicted by IPA analysis.

  Master Regulator   Molecule Type          Predicted Activation State   Activation *z*-Score   *p*-Value
  ------------------ ---------------------- ---------------------------- ---------------------- ---------------
  GPR68              G-protein complex      Inhibited                    −2.12                  1.09 × 10^−4^
  MARK2              Kinase                 Inhibited                    −2.33                  2.67 × 10^−4^
  miR-149-5p         Mature microRNA        Inhibited                    −2.53                  1.36 × 10^−4^
  ATG7               Enzyme                 Inhibited                    −2.65                  7.88 × 10^−6^
  Smad2/3-Smad4      Complex                Inhibited                    −2.83                  3.02 × 10^−4^
  PDE2A              Enzyme                 Activated                    +2.53                  4.07 × 10^−5^
  ELMO1              Other                  Activated                    +2.53                  8.06 × 10^−5^
  DOCK5              Other                  Activated                    +2.53                  8.14 × 10^−5^
  FARP2              Other                  Activated                    +2.53                  1.07 × 10^−4^
  ARHGEF6/7          Group                  Activated                    +2.53                  1.07 × 10^−5^
  BAIAP2             Kinase                 Activated                    +2.33                  2.44 × 10^−4^
  RAC1               Enzyme                 Activated                    +2.33                  2.47 × 10^−4^
  Hif                Complex                Activated                    +2.33                  3.28 × 10^−4^
  ADORA1             G-protein complex      Activated                    +2.33                  4.12 × 10^−4^
  NOX4               Enzyme                 Activated                    +2.31                  3.59 × 10^−6^
  NFE2L2             Transcription factor   Activated                    +2.23                  1.07 × 10^−5^
  MYCN               Transcription factor   Activated                    +2.00                  3.85 × 10^−5^
  HSF1               Transcription factor   Activated                    +2.00                  1.33 × 10^−3^
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###### 

List of primers for real-time PCR.

  Gene         5′-Forward-3′            5′-Reverse-3′
  ------------ ------------------------ -----------------------
  *GSTM3*      TTGAGGCTTTGGAGAAAATC     TGAAAAGAGCAAAGCAAGAG
  *HSP90AA1*   ATATCACAGGTGAGACCAAG     GTGACTGACACTAAAGTCTTC
  *HSP90AB1*   TCTATTACATCACTGGTGAGAG   CTCTTCCCATCAAATTCCTTG
  *PSMB4*      ACGCTGATTTCCAGTATTTG     CCATGAATGAATAGCTCTAGG
  *PSMD1*      CCAGTTATTGGATAACCCAG     CTCCAATAGAGAGTGGTTTG
  *USP14*      AGCCCTTAGAGATTTGTTTG     ATCCTGTTGAAGATACTGTCC
  *PKM1*       GAGGCAGCCATGTTCCAC       TGCCAGACTCCGTCAGAACT
  *PKM2*       CAGAGGCTGCCATCTACCAC     CCAGACTTGGTGAGGACGAT
  *PRDX1*      GGGTCAATACACCTAAGAAAC    CTTCATCAGCCTTTAAGACC
  *18S rRNA*   CAGAAGGATGTAAAGGATGG     TATTTCTTCTTGGACACACC

[^1]: These authors contributed equally to this work.
